U.S. Markets close in 3 hrs 1 mins

Prothena Corporation plc (PRTA)

NASDAQ Global Select - NASDAQ Global Select Real Time Price. Currency in USD
Add to watchlist
55.065+1.235 (+2.294%)
As of 12:56PM EDT. Market open.
People also watch
PTLAAGIORAREPTCTONCE

Prothena Corporation plc

Adelphi Plaza
Upper George's Street
Dún Laoghaire A96 T927
Ireland
353 1 236 2500
http://www.prothena.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees96

Key Executives

NameTitlePayExercisedAge
Mr. Gene G. Kinney Ph.D.Chief Exec. Officer, Pres and Director645.61k1.43M48
Mr. Tran B. Nguyen M.B.A.Chief Financial Officer532.64kN/A43
Mr. Arthur W. Homan J.D.Chief Legal Officer492.24k614.19k58
Ms. Carol D. KarpChief Regulatory Officer324.49kN/A64
Ms. Karin L. Walker CPAChief Accounting Officer and ControllerN/AN/A54
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinson’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.

Corporate Governance

Prothena Corporation plc’s ISS Governance QualityScore as of August 1, 2017 is 3. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 4; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.